Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




AI to Transform Skin Cancer Diagnosis in Remote Areas

By LabMedica International staff writers
Posted on 29 Jul 2025

Many patients living in remote regions lack timely access to dermatological care, often facing long wait times and delayed diagnoses for potentially serious conditions like skin cancer. More...

Healthcare backlogs and stretched resources across the UK further complicate access to early detection services. In areas with limited or no medical infrastructure, especially in rural or underserved locations, the challenge of diagnosing skin conditions accurately and efficiently becomes even more pronounced. With limited internet access in many of these regions, traditional telemedicine models often fall short. Now, researchers have developed a new device that empowers individuals to monitor skin conditions from home using artificial intelligence (AI), reducing diagnostic delays and expanding access to care.

The device, developed by researchers at Heriot-Watt University (Edinburgh, Scotland, UK) along with collaborators, uses low-cost Raspberry Pi hardware combined with state-of-the-art image classification algorithms to assess skin lesions in real-time. Originally inspired by earlier work in accessible translation technologies and studies in Tiny Machine Learning, the project applies underexplored AI capabilities to dermatology. Patients take images of skin conditions using a camera connected to the device, which analyzes the photos locally — independent of Wi-Fi — by comparing them to a vast database of thousands of skin lesion images. Diagnostic results are delivered within seconds, with findings securely shared with local general practitioners for follow-up treatment planning. A prototype of the device has been successfully demonstrated, making it the first system of its kind designed to deliver AI-based skin diagnoses without internet connectivity.

While the tool has not yet been tested in clinical settings, its diagnostic accuracy currently stands at up to 85%, with further improvements expected through access to larger skin lesion datasets and more advanced machine learning models. The team is in discussions with NHS Scotland to begin the ethical approval process for pilot testing. The long-term plan is to roll out the system first in remote Scottish regions before expanding to international locations with limited access to dermatological care. The device could also benefit patients who are housebound or have mobility challenges, enabling caregivers to assist in diagnosis. The ultimate goal is to establish a resilient, cost-effective diagnostic solution capable of operating independently in resource-limited settings.

"There's a lot being done with AI and medical scans like X-rays and MRIs, but relatively little using photographs of skin,” said Tess Watt, a researcher at Heriot-Watt University who has developed AI-driven tools to diagnose skin conditions. "If we can empower people to monitor skin conditions from their own homes using AI, we can dramatically reduce delays in diagnosis."

Related Links:
Heriot-Watt University


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.